Works matching IS 01676997 AND DT 2025 AND VI 43 AND IP 2

Results: 27

Does anamorelin have beneficial effects in advanced cancer patients with systemic inflammation in the real world?

Published in:

2025

By:

Amano, Koji;
Naito, Tateaki;
Baracos, Vickie E.

Publication type:

Letter

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 435, doi. 10.1007/s10637-025-01533-8

By:

Azad, Arun A.;
Gurney, Howard;
Underhill, Craig;
Horvath, Lisa;
Voskoboynik, Mark;
Li, Xinghai;
King, Ivan;
Shao, Lisa;
Dai, Yiyun;
Perabo, Frank

Publication type:

Article

The up-regulated expression level of deubiquitinating enzyme USP46 induces the apoptosis of A549 cells by TRAF6.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 328, doi. 10.1007/s10637-025-01532-9

By:

Zhao, Xuan;
Li, Yanan;
Gu, Dandan;
Wang, Xiaoru;
Han, Guangxin;
Yao, Yasen;
Ren, Limei;
Yao, Qingguo;
Li, Xiaobing;
Qi, Yonghao

Publication type:

Article

MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 348, doi. 10.1007/s10637-025-01531-w

By:

Piri, Reyhane;
Shahidi, Minoo;
Pooraskari, Zahra;
Habibi, Sina

Publication type:

Article

Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignancies.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 318, doi. 10.1007/s10637-025-01529-4

By:

Ma, Li;
Ma, Juan;
Feng, Dingqing;
Xue, Xin

Publication type:

Article

Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 405, doi. 10.1007/s10637-025-01528-5

By:

Awad, Abdelaziz A.;
Shaban, Ahmed Yasser;
Mohammed, Fatma;
Marey, Mohamed Mahmoud;
Aldemerdash, Mohamed A.;
Abbas, Ahmed W.;
Saeed, Omar;
Saeed, Abdelrahman;
Elhady, Mahmoud M.;
Sharabati, Israa;
Hamed, Mohamed;
Abou-Shanab, Ahmed R. A.;
Bahnasy, Ahmed;
Abdelgawad, Hussien Ahmed H.

Publication type:

Article

PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 337, doi. 10.1007/s10637-025-01526-7

By:

Shim, Susy;
Reinacher-Schick, Anke;
Kraeft, Anna-Lena;
Per Pfeiffer;
Tarpgaard, Line Schmidt;
Ettrich, Thomas Jens;
Kestler, Angelika;
Christensen, Signe;
Jandu, Haatisha;
Nawabi, Mubeen;
Roest, Nicklas Lindland;
Damstrup, Lars;
Vestlev, Peter Michael;
Brünner, Nils;
Stenvang, Jan;
Ladekarl, Morten

Publication type:

Article

US FDA–accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 311, doi. 10.1007/s10637-025-01524-9

By:

Hakariya, Hayase;
Ozaki, Akihiko;
Tanimoto, Tetsuya

Publication type:

Article

Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 394, doi. 10.1007/s10637-025-01523-w

By:

Yao, Ningning;
Jing, Na;
Lin, Jianzhong;
Niu, Wenxia;
Yan, Wenxing;
Yuan, Hongqin;
Xiong, Zeyi;
Hou, Qing;
Qiao, Xiaxi;
Liu, Quanming;
Cao, Jianzhong;
Li, Ning

Publication type:

Article

Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 293, doi. 10.1007/s10637-025-01522-x

By:

Wu, Zhaoquan;
Lei, Haibo;
Li, Ronghui;
Liu, Xiang;
Wang, Chunjiang

Publication type:

Article

Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 425, doi. 10.1007/s10637-025-01521-y

By:

Yuejian;
Zhao, Jijun;
Wu, Tao;
Zhang, Dongdong

Publication type:

Article

Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 301, doi. 10.1007/s10637-025-01520-z

By:

Li, Anran;
Yu, Mingmin;
Zhao, Yue;
Wu, Shuangshuang;
Wang, Guan;
Wang, Liping

Publication type:

Article

Correction to: Clinical research progress of fruquintinib in the treatment of malignant tumors.

Published in:

2025

By:

Zhao, Shihao;
Wang, Wenhui;
Li, Jingyi;
Li, Zhigang;
Liu, Zhanbo;
Zhang, Shunchao;
Chen, Zhaoqi;
Wang, Hongling;
Wang, Xiangqi;
Wang, Juntao

Publication type:

Correction Notice

First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 284, doi. 10.1007/s10637-025-01518-7

By:

Johnson, Melissa;
Hong, David;
Braña, Irene;
Schöffski, Patrick;
Galvao, Vladimir;
Rangwala, Fatima;
Ma, Bo;
Hernandez, Robert;
Kamat, Asha;
Kato, Kazunobu;
Schreiber, Taylor H.;
Pandite, Lini;
Siu, Lillian L.

Publication type:

Article

Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 276, doi. 10.1007/s10637-025-01517-8

By:

Pan, Yong;
Li, Wei;
Wu, Zhaoquan;
Sun, Wei;
He, Binsheng;
Wang, Chunjiang

Publication type:

Article

Challenging and new opportunities for prodrug technology.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 365, doi. 10.1007/s10637-025-01515-w

By:

Li, Helin;
Shen, Xuelian;
Chu, Yu;
Yuan, Panhong;
Shuai, Qi

Publication type:

Article

Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 357, doi. 10.1007/s10637-025-01514-x

By:

Yang, Peiyuan;
Li, Yongchao

Publication type:

Article

From development to clinical success: the journey of established and next-generation BTK inhibitors.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 377, doi. 10.1007/s10637-025-01513-y

By:

Gupta, Shivani;
Sharma, Arpit;
Shukla, Alok;
Mishra, Abha;
Singh, Amit

Publication type:

Article

A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 250, doi. 10.1007/s10637-025-01512-z

By:

Liu, Dan;
Gong, Jifang;
Zhang, Jian;
Shu, Yongqian;
Wu, Hao;
Liu, Tianshu;
Xu, Yanhua;
Zhang, Lijia;
Li, Min;
Hu, Xichun;
Shen, Lin

Publication type:

Article

Clinical features, diagnosis, and treatment of pembrolizumab induced autoimmune encephalitis.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 191, doi. 10.1007/s10637-025-01511-0

By:

Zou, Li;
Rao, Xianlin;
Zhao, Xiyue

Publication type:

Article

Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 214, doi. 10.1007/s10637-025-01510-1

By:

Wang, Xin;
Bai, Zhigang;
Deng, Wei;
Wang, Xinfeng

Publication type:

Article

Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 243, doi. 10.1007/s10637-025-01509-8

By:

Kim, Jae Hyun;
Han, Ja-Young;
Kwon, Jae-Hee;
Kim, Myeong Gyu

Publication type:

Article

HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 223, doi. 10.1007/s10637-025-01508-9

By:

Oliveira, Leilane Sales;
Oliveira-Silva, João Marcos;
Almeida-Souza, Hebreia Oliveira;
Martins, Mario Machado;
Chiminazo, Carolina Berraut;
Fonseca, Rafael;
Souza, Carlos Vinicius Expedito de;
Aissa, Alexandre Ferro;
Bastos, Luciana Machado;
Ionta, Marisa;
Almeida Lima, Graziela Domingues de;
Castro-Gamero, Angel Mauricio

Publication type:

Article

A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 262, doi. 10.1007/s10637-025-01507-w

By:

Huang, Huoying;
Zhou, Yuxin;
Shang, Chengzhang;
Zhang, Yifu;
Shen, Yuelei

Publication type:

Article

Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 181, doi. 10.1007/s10637-025-01506-x

By:

Ma, Lixia;
Zhang, Yu;
Fang, Yong;
Hao, Chunyi;
Fan, Qingxia;
Jiang, Da;
Lu, Liqin;
Su, Fang;
Yang, Chen;
Liu, Zhenru;
Tian, Ji;
Sun, Xiyang;
Sun, Shuguang;
Cheng, Ying

Publication type:

Article

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Published in:

Investigational New Drugs, 2025, v. 43, n. 2, p. 199, doi. 10.1007/s10637-024-01495-3

By:

Yang, Lu;
Feng, Yanlong;
Liu, Xuewen;
Zhang, Qin;
Liu, Yaqin;
Zhang, Xing;
Li, Ping;
Chen, Dongsheng

Publication type:

Article

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.

Published in:

2025

By:

Thein, Kyaw Z.;
Karp, Daniel D.;
Tsimberidou, Apostolia;
Gong, Jing;
Sulovic, Selma;
Shah, Jatin;
Milton, Denái R.;
Hong, David S.;
Janku, Filip;
McQuinn, Lacey;
Stephen, Bettzy A.;
Colen, Rivka;
Carter, Brett W.;
Yap, Timothy A.;
Piha-Paul, Sarina A.;
Fu, Siqing;
Meric-Bernstam, Funda;
Naing, Aung

Publication type:

Correction Notice